← Back to Patent Explorer
US5364346A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for the continuous and discontinuous administration of insulin to the human body

Assignee: Individual
•
Filing: 1994-03-16
•
Granted: 1994-11-15
•
Expires: 2014-03-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process for the administration of insulin to the human body, particularly the discontinuous administration of insulin to the body, is disclosed. An apparatus for carrying out the process includes either dosing means for metering, or a display for otherwise indicating, the optimum quantity of insulin for a patient. The apparatus permits the measurement of one or more blood sugar levels, compares such blood sugar levels with a series of reference values, and controls the dosing means or display appropriately. In addition, the input data values, as well as the administered amounts of insulin, can be stored and compared with each other over a long period of time and/or evaluated by a computer.

Inventors

  • 👤 Jurgen Schrezenmeir

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 22:42
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/168; A61M5/172; A61M5/1723

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 408 words
A process for the administration of insulin to a patient based upon a determination of a blood carbohydrate level of the patient, comprising the steps of: (a) administering an initial series of dosages of insulin to the patient; (b) measuring the blood carbohydrate level of the patient during said administering step; (c) recording and storing the blood carbohydrate levels obtained during said measuring step; (d) determining a new quantity of insulin to be administered based upon an insulin carbohydrate equivalent level of the patient obtained in said measuring step in accordance with the formula: ##EQU3## wherein, M is the patient's initial meal; I is the initially considered day; IBO (M, I-1) is the corrected insulin dose on the day preceding the M-th meal, so that the IBO (M, I-1) value is the quantity of insulin administered to the patient at meal M on a preceding day I-1; CORI (M, I-1) is the corrected insulin dose on the basis of deviation from a reference carbohydrate level determined from a blood sugar level measured directly before the M-th meal on the previous day using an insulin-blood sugar equivalent so that the CORI (M, I-1) value is the product of said insulin-blood sugar equivalent and the difference between the blood sugar level and the reference carbohydrate level, with the reference carbohydrate level being an optimal blood sugar level for the patient necessary for determining the initial insulin dose, and the insulin-blood sugar equivalent being the quotient of a value of insulin given to the patient and a resulting change in the blood sugar level of the patient; COH (M, I-1) is the quantity of carbohydrate in the food consumed in the M-th meal on the previous day; and, CORI (M+1, I-1) is the correcting insulin dose administered on the previous day at the beginning of the (M+1) meal because of the deviation of the blood carbohydrate level from the reference value, so that a quantity of insulin IBO (M, I), at meal M and day I is determined from the product COH (M, I) and the insulin carbohydrate equivalent level ICOHE (M, I), with COH being the quantity of carbohydrate in food consumed in the meal M on the day I; and, (e) administering to the patient the new quantity of insulin, as determined by the insulin carbohydrate equivalent level in said determining step, based upon a desired insulin per unit of carbohydrate for the blood of the patient following treatment.
Claim 2
Dependent Claim 408 words
A process for the administration of insulin to a patient based upon a determination of a blood carbohydrate level of the patient, comprising the steps of: (a) administering an initial series of dosages of insulin to the patient; (b) measuring the blood carbohydrate level of the patient during said administering step; (c) recording and storing the blood carbohydrate levels obtained during said measuring step; (d) determining a new quantity of insulin to be administered based upon an insulin carbohydrate equivalent level of the patient obtained in said measuring step in accordance with the formula: ##EQU3## wherein, M is the patient's initial meal; I is the initially considered day; IBO (M, I-1) is the corrected insulin dose on the day preceding the M-th meal, so that the IBO (M, I-1) value is the quantity of insulin administered to the patient at meal M on a preceding day I-1; CORI (M, I-1) is the corrected insulin dose on the basis of deviation from a reference carbohydrate level determined from a blood sugar level measured directly before the M-th meal on the previous day using an insulin-blood sugar equivalent so that the CORI (M, I-1) value is the product of said insulin-blood sugar equivalent and the difference between the blood sugar level and the reference carbohydrate level, with the reference carbohydrate level being an optimal blood sugar level for the patient necessary for determining the initial insulin dose, and the insulin-blood sugar equivalent being the quotient of a value of insulin given to the patient and a resulting change in the blood sugar level of the patient; COH (M, I-1) is the quantity of carbohydrate in the food consumed in the M-th meal on the previous day; and, CORI (M+1, I-1) is the correcting insulin dose administered on the previous day at the beginning of the (M+1) meal because of the deviation of the blood carbohydrate level from the reference value, so that a quantity of insulin IBO (M, I), at meal M and day I is determined from the product COH (M, I) and the insulin carbohydrate equivalent level ICOHE (M, I), with COH being the quantity of carbohydrate in food consumed in the meal M on the day I; and, (e) administering to the patient the new quantity of insulin, as determined by the insulin carbohydrate equivalent level in said determining step, based upon a desired insulin per unit of carbohydrate for the blood of the patient following treatment.

References Cited (Backward Citations)

US4018223A Cited
US4206755A Cited
US4403984A Cited
US4475901A Cited
US4526568A Cited
US4538616A Cited
US4722734A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-11-14 1998-05-16 1998-11-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-11-14 2002-05-16 2002-11-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-11-14 2006-05-16 2006-11-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag